OncoMatch/Clinical Trials/NCT06839456

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Is NCT06839456 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for leukemia.

Treatment: Phase 1 Dose Level 1 · Phase 1 Dose Level 2 · Phase 1 Dose Level 3 · Phase 2 Maximum Tolerated Dose determined in Phase 1 · Phase 2 Established Dose from prior study, NCT03810196 — The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.